Eli Lilly, Nvidia Launch LillyPod: Pharma's First 'AI Factory' in Indianapolis

Tip Ranks
2026.02.27 09:14

Eli Lilly and Nvidia have launched LillyPod, the pharmaceutical industry's first AI Factory, in Indianapolis. This supercomputer, equipped with 1,016 Nvidia GPUs, aims to revolutionize drug discovery by enabling scientists to explore billions of hypotheses simultaneously. LillyPod is designed to handle the full AI lifecycle and is part of Lilly's strategy to enhance its AI capabilities. The initiative reflects a competitive push in the pharmaceutical sector, with other companies like Pfizer and Sanofi also partnering with Nvidia. Analysts are optimistic about Eli Lilly's stock, predicting a 23.4% upside potential.

Drug giant Eli Lilly (LLY) and chip giant Nvidia (NVDA) opened LillyPod, the pharmaceutical industry's most powerful supercomputer, in Indianapolis yesterday. This 'AI Factory' is built on DGX SuperPOD with 1,016 Nvidia Blackwell Ultra GPUs (graphics processing units), to power scientific research and accelerate the future of medicine.

Claim 50% Off TipRanks Premium

  • Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
  • Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

What Is LillyPod?

Plans for LillyPod were announced last fall, with its live, production-scale debut marking a pivotal shift in Lilly's AI strategy. It is a first of its kind AI Factory, wholly owned and operated by a pharmaceutical company. Lilly positions LillyPod not as mere IT infrastructure, but as a revolutionary scientific instrument, like a telescope or microscope, that transforms drug discovery.

LillyPod handles the full AI lifecycle, from large-scale model training to high-volume inference. Traditional wet labs test roughly 2,000 molecular ideas per target annually, while LillyPod lets scientists explore billions of hypotheses in parallel in the "dry lab."

LillyPod uses nearly 5,000 fiber cable connections, weighing over 1,000 pounds, for its links. Lilly targets 100% renewable power by 2030 via efficient liquid cooling, with minimal added energy use.

Lilly Steps Ahead in AI Arms Race

Lilly also highlighted early signs of strong demand and impact. LillyPod went live on day one, fueling applications in genomics, molecule and peptide design, single-cell biology, imaging, manufacturing, and enterprise operations. This builds on Lilly and Nvidia's recent co-innovation lab in South San Francisco, reflecting Lilly's push beyond pilots to enterprise-scale AI with robust talent, governance, and responsible AI frameworks.

LillyPod signals pharma's AI arms race, where rivals like Pfizer (PFE) and Sanofi (SNY) have also partnered with Nvidia, potentially slashing drug discovery timelines.

Is LLY Stock Worth Buying?

Analysts remain highly optimistic about Eli Lilly's long-term prospects. On TipRanks, LLY stock has a Strong Buy consensus rating based on 18 Buys and three Hold ratings. The average Eli Lilly price target of $1,261 implies 23.4% upside potential from current levels. Over the past year, LLY shares have surged 12.9%.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.